We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Madrigal (MDGL) This Earnings Season?
Read MoreHide Full Article
Madrigal Pharmaceuticals, Inc. (MDGL - Free Report) is expected to report third-quarter 2017 results on Nov 9, after the market closes.
So far this year, the company’s share price has increased significantly by 215.5%, compared with the industry’s gain of 1.5%.
Factors to Consider
Madrigal has no approved product in its portfolio, so its complete focus on the third-quarter earnings call will be on its lead pipeline candidate, MGL-3196.
Madrigal’s lead pipeline candidate MGL-3196 is a liver-directed THR-ß agonist, which is being developed in phase II studies for the treatment of non-alcoholic steatohepatitis (NASH).
Additionally, it is developing MGL-3196 for dyslipidemia, particularly genetic dyslipidemias such as familial hypercholesterolemia, (FH) including both homozygous and heterozygous forms of the disease. A phase II study on heterozygous familial hypercholesterolemia (HeFH) is also ongoing.
In September 2017, the independent Data Safety Monitoring Board (“DSMB”) recommended to continue both the NASH and HeFH clinical studies with no modifications to either protocol. The company announced the completion of enrolment for HeFH study. While top-line results from NASH are expected in 2017, the same from the HeFH study are expected by early 2018. The positive results will to support the phase III study for MGL-3196 for both the indications.
Earnings Whispers
Our proven model does not conclusively show an earnings beat for Madrigal this quarter. This is because a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — for this to happen. That is not the case here, as you will see below.
Zacks ESP: Madrigal has an Earnings ESP of 0.00%. That is because the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 84 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Madrigal carries a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
Note that we caution against stocks with Zacks Ranks #4 or 5 (Sell-rated) going into an earnings announcement, especially when the company is seeing a negative estimate revision.
Madrigal Pharmaceuticals, Inc. Price and EPS Surprise
Here are some companies to consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:
Agenus Inc. (AGEN - Free Report) has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is expected to release results on Nov 7.
Amedisys, Inc. (AMED - Free Report) has an Earnings ESP of +0.62% and a Zacks Rank #2. The company is expected to release results on Nov 7.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
What's in Store for Madrigal (MDGL) This Earnings Season?
Madrigal Pharmaceuticals, Inc. (MDGL - Free Report) is expected to report third-quarter 2017 results on Nov 9, after the market closes.
So far this year, the company’s share price has increased significantly by 215.5%, compared with the industry’s gain of 1.5%.
Factors to Consider
Madrigal has no approved product in its portfolio, so its complete focus on the third-quarter earnings call will be on its lead pipeline candidate, MGL-3196.
Madrigal’s lead pipeline candidate MGL-3196 is a liver-directed THR-ß agonist, which is being developed in phase II studies for the treatment of non-alcoholic steatohepatitis (NASH).
Additionally, it is developing MGL-3196 for dyslipidemia, particularly genetic dyslipidemias such as familial hypercholesterolemia, (FH) including both homozygous and heterozygous forms of the disease. A phase II study on heterozygous familial hypercholesterolemia (HeFH) is also ongoing.
In September 2017, the independent Data Safety Monitoring Board (“DSMB”) recommended to continue both the NASH and HeFH clinical studies with no modifications to either protocol. The company announced the completion of enrolment for HeFH study. While top-line results from NASH are expected in 2017, the same from the HeFH study are expected by early 2018. The positive results will to support the phase III study for MGL-3196 for both the indications.
Earnings Whispers
Our proven model does not conclusively show an earnings beat for Madrigal this quarter. This is because a stock needs to have both — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — for this to happen. That is not the case here, as you will see below.
Zacks ESP: Madrigal has an Earnings ESP of 0.00%. That is because the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 84 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Madrigal carries a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
Note that we caution against stocks with Zacks Ranks #4 or 5 (Sell-rated) going into an earnings announcement, especially when the company is seeing a negative estimate revision.
Madrigal Pharmaceuticals, Inc. Price and EPS Surprise
Madrigal Pharmaceuticals, Inc. Price and EPS Surprise | Madrigal Pharmaceuticals, Inc. Quote
Stocks to Consider
Here are some companies to consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) has an Earnings ESP of +2.02% and a Zacks Rank #3. The company is scheduled to release results on Nov 7. You can see the complete list of today’s Zacks #1 Rank stocks here.
Agenus Inc. (AGEN - Free Report) has an Earnings ESP of +8.11% and a Zacks Rank #2. The company is expected to release results on Nov 7.
Amedisys, Inc. (AMED - Free Report) has an Earnings ESP of +0.62% and a Zacks Rank #2. The company is expected to release results on Nov 7.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>